Foghorn Therapeutics Net Income
| FHTX Stock | USD 5.26 0.16 2.95% |
As of the 13th of February 2026, Foghorn Therapeutics shows the Downside Deviation of 3.61, mean deviation of 3.55, and Coefficient Of Variation of 1240.29. Foghorn Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Foghorn Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 6.5162 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -78 M | -81.9 M | |
| Net Loss | -98 M | -102.9 M | |
| Net Loss | -78 M | -81.9 M | |
| Net Loss | (1.81) | (1.91) | |
| Net Income Per E B T | 0.94 | 0.83 |
Foghorn | Net Income | Build AI portfolio with Foghorn Stock |
The evolution of Net Income for Foghorn Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Foghorn Therapeutics compares to historical norms and industry peers.
Latest Foghorn Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Foghorn Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Foghorn Therapeutics financial statement analysis. It represents the amount of money remaining after all of Foghorn Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Foghorn Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Foghorn Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (86.62 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Foghorn Net Income Regression Statistics
| Arithmetic Mean | (53,647,920) | |
| Coefficient Of Variation | (60.31) | |
| Mean Deviation | 29,213,906 | |
| Median | (26,337,000) | |
| Standard Deviation | 32,355,773 | |
| Sample Variance | 1046.9T | |
| Range | 82.5M | |
| R-Value | (0.84) | |
| Mean Square Error | 331.3T | |
| R-Squared | 0.70 | |
| Significance | 0.000026 | |
| Slope | (5,373,662) | |
| Total Sum of Squares | 16750.3T |
Foghorn Net Income History
Other Fundumenentals of Foghorn Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Foghorn Therapeutics Net Income component correlations
Foghorn Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Foghorn Therapeutics is extremely important. It helps to project a fair market value of Foghorn Stock properly, considering its historical fundamentals such as Net Income. Since Foghorn Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Foghorn Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Foghorn Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Foghorn Therapeutics. Market participants price Foghorn higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Foghorn Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.14) | Revenue Per Share | Quarterly Revenue Growth 0.044 | Return On Assets | Return On Equity |
The market value of Foghorn Therapeutics is measured differently than its book value, which is the value of Foghorn that is recorded on the company's balance sheet. Investors also form their own opinion of Foghorn Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Foghorn Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Foghorn Therapeutics' market value can be influenced by many factors that don't directly affect Foghorn Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Foghorn Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Foghorn Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Foghorn Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Foghorn Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Foghorn Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Foghorn Therapeutics.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Foghorn Therapeutics on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Foghorn Therapeutics or generate 0.0% return on investment in Foghorn Therapeutics over 90 days. Foghorn Therapeutics is related to or competes with Immuneering Corp, Pyxis Oncology, Assembly Biosciences, Zura Bio, Arcturus Therapeutics, Sagimet Biosciences, and Humacyte. Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting geneti... More
Foghorn Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Foghorn Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Foghorn Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.61 | |||
| Information Ratio | 0.0643 | |||
| Maximum Drawdown | 31.12 | |||
| Value At Risk | (5.56) | |||
| Potential Upside | 8.6 |
Foghorn Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Foghorn Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Foghorn Therapeutics' standard deviation. In reality, there are many statistical measures that can use Foghorn Therapeutics historical prices to predict the future Foghorn Therapeutics' volatility.| Risk Adjusted Performance | 0.0738 | |||
| Jensen Alpha | 0.2824 | |||
| Total Risk Alpha | (0.04) | |||
| Sortino Ratio | 0.0883 | |||
| Treynor Ratio | 0.2572 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Foghorn Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Foghorn Therapeutics February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0738 | |||
| Market Risk Adjusted Performance | 0.2672 | |||
| Mean Deviation | 3.55 | |||
| Semi Deviation | 3.4 | |||
| Downside Deviation | 3.61 | |||
| Coefficient Of Variation | 1240.29 | |||
| Standard Deviation | 4.96 | |||
| Variance | 24.55 | |||
| Information Ratio | 0.0643 | |||
| Jensen Alpha | 0.2824 | |||
| Total Risk Alpha | (0.04) | |||
| Sortino Ratio | 0.0883 | |||
| Treynor Ratio | 0.2572 | |||
| Maximum Drawdown | 31.12 | |||
| Value At Risk | (5.56) | |||
| Potential Upside | 8.6 | |||
| Downside Variance | 13.02 | |||
| Semi Variance | 11.55 | |||
| Expected Short fall | (4.58) | |||
| Skewness | 1.74 | |||
| Kurtosis | 6.34 |
Foghorn Therapeutics Backtested Returns
Foghorn Therapeutics appears to be moderately volatile, given 3 months investment horizon. Foghorn Therapeutics secures Sharpe Ratio (or Efficiency) of 0.053, which denotes the company had a 0.053 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Foghorn Therapeutics, which you can use to evaluate the volatility of the firm. Please utilize Foghorn Therapeutics' Mean Deviation of 3.55, coefficient of variation of 1240.29, and Downside Deviation of 3.61 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Foghorn Therapeutics holds a performance score of 4. The firm shows a Beta (market volatility) of 1.51, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Foghorn Therapeutics will likely underperform. Please check Foghorn Therapeutics' total risk alpha, as well as the relationship between the downside variance and daily balance of power , to make a quick decision on whether Foghorn Therapeutics' price patterns will revert.
Auto-correlation | -0.39 |
Poor reverse predictability
Foghorn Therapeutics has poor reverse predictability. Overlapping area represents the amount of predictability between Foghorn Therapeutics time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Foghorn Therapeutics price movement. The serial correlation of -0.39 indicates that just about 39.0% of current Foghorn Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.39 | |
| Spearman Rank Test | -0.26 | |
| Residual Average | 0.0 | |
| Price Variance | 0.19 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Foghorn Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Foghorn Therapeutics reported net income of (86.62 Million). This is 125.38% lower than that of the Biotechnology sector and 223.66% lower than that of the Health Care industry. The net income for all United States stocks is 115.17% higher than that of the company.
Foghorn Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Foghorn Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Foghorn Therapeutics could also be used in its relative valuation, which is a method of valuing Foghorn Therapeutics by comparing valuation metrics of similar companies.Foghorn Therapeutics is currently under evaluation in net income category among its peers.
Foghorn Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Foghorn Therapeutics from analyzing Foghorn Therapeutics' financial statements. These drivers represent accounts that assess Foghorn Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Foghorn Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 850.1M | 265.4M | 270.7M | 259.1M | 298.0M | 536.5M | |
| Enterprise Value | 807.3M | 264.6M | 235.5M | 240.8M | 276.9M | 514.6M |
Foghorn Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Foghorn Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Foghorn Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Foghorn Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Foghorn Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Foghorn Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Foghorn Therapeutics' value.| Shares | Alphabet Inc | 2025-06-30 | 500.9 K | Birchview Capital, Lp | 2025-06-30 | 310.9 K | Dafna Capital Management Llc | 2025-06-30 | 300.5 K | Northern Trust Corp | 2025-06-30 | 286.7 K | Jacobs Levy Equity Management, Inc. | 2025-06-30 | 192.7 K | Sio Capital Management, Llc | 2025-06-30 | 122.9 K | Wellington Management Company Llp | 2025-06-30 | 118.3 K | Ameriprise Financial Inc | 2025-06-30 | 112.2 K | Scs Capital Management Llc | 2025-06-30 | 107 K | Flagship Ventures Management, Inc. | 2025-06-30 | 12.7 M | Fmr Inc | 2025-06-30 | 5.5 M |
Foghorn Fundamentals
| Return On Equity | -4.7 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (2.94) % | ||||
| Operating Margin | (2.27) % | ||||
| Current Valuation | 159.76 M | ||||
| Shares Outstanding | 58.58 M | ||||
| Shares Owned By Insiders | 18.03 % | ||||
| Shares Owned By Institutions | 70.17 % | ||||
| Number Of Shares Shorted | 1.21 M | ||||
| Price To Book | 10.71 X | ||||
| Price To Sales | 12.95 X | ||||
| Revenue | 22.6 M | ||||
| Gross Profit | (59.41 M) | ||||
| EBITDA | (97.17 M) | ||||
| Net Income | (86.62 M) | ||||
| Cash And Equivalents | 373.5 M | ||||
| Cash Per Share | 8.94 X | ||||
| Total Debt | 37.13 M | ||||
| Debt To Equity | 2.19 % | ||||
| Current Ratio | 6.84 X | ||||
| Book Value Per Share | (1.59) X | ||||
| Cash Flow From Operations | (100.41 M) | ||||
| Short Ratio | 6.17 X | ||||
| Earnings Per Share | (1.14) X | ||||
| Target Price | 11.67 | ||||
| Number Of Employees | 112 | ||||
| Beta | 3.03 | ||||
| Market Capitalization | 317.51 M | ||||
| Total Asset | 283.98 M | ||||
| Retained Earnings | (558.18 M) | ||||
| Working Capital | 182.61 M | ||||
| Net Asset | 283.98 M |
About Foghorn Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Foghorn Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Foghorn Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Foghorn Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.